Jupiter Asset Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $115M | Sell |
529,252
-6,324
| -1% | -$1.4M | 0.61% | 40 |
|
|
2025
Q4 | $122M | Buy |
535,576
+533,279
| +23,216% | +$121M | 0.98% | 20 |
|
|
2025
Q3 | $532K | Sell |
2,297
-290,801
| -99% | -$59.2M | ﹤0.01% | 377 |
|
|
2025
Q2 | $54.4M | Buy |
293,098
+185,088
| +171% | +$34.4M | 0.45% | 73 |
|
|
2025
Q1 | $22.6M | Sell |
108,010
-168,659
| -61% | -$32.8M | 0.22% | 142 |
|
|
2024
Q4 | $49.2M | Buy |
+276,669
| New | +$50.9M | 0.48% | 64 |
|
|
2024
Q3 | – | Sell |
-1,189
| Closed | -$204K | – | 398 |
|
|
2024
Q2 | $204K | Buy |
+1,189
| New | +$197K | ﹤0.01% | 381 |
|
|
2021
Q2 | – | Sell |
-3,717
| Closed | -$402K | – | 571 |
|
|
2021
Q1 | $402K | Sell |
3,717
-423,211
| -99% | -$45.3M | ﹤0.01% | 504 |
|
|
2020
Q4 | $45.7M | Buy |
426,928
+46,487
| +12% | +$4.47M | 0.46% | 55 |
|
|
2020
Q3 | $33.3M | Buy |
380,441
+158,155
| +71% | +$14.9M | 0.35% | 76 |
|
|
2020
Q2 | $21.8M | Buy |
222,286
+11,931
| +6% | +$1.05M | 0.73% | 27 |
|
|
2020
Q1 | $16M | Buy |
210,355
+500
| +0.2% | +$42.6K | 0.69% | 34 |
|
|
2019
Q4 | $18.6M | Buy |
209,855
+583
| +0.3% | +$48.4K | 0.57% | 36 |
|
|
2019
Q3 | $15.8M | Buy |
209,272
+4,907
| +2% | +$336K | 0.52% | 47 |
|
|
2019
Q2 | $14.9M | Buy |
204,365
+32,113
| +19% | +$2.52M | 0.47% | 59 |
|
|
2019
Q1 | $13.9M | Sell |
172,252
-122,018
| -41% | -$9.98M | 0.45% | 59 |
|
|
2018
Q4 | $26.8M | Sell |
294,270
-21,202
| -7% | -$1.86M | 0.94% | 22 |
|
|
2018
Q3 | $29.7M | Sell |
315,472
-5,202
| -2% | -$493K | 0.85% | 26 |
|
|
2018
Q2 | $29.7M | Sell |
320,674
-72,570
| -18% | -$7.09M | 0.87% | 20 |
|
|
2018
Q1 | $37.2M | Sell |
393,244
-143,090
| -27% | -$15.7M | 1.13% | 14 |
|
|
2017
Q4 | $51.9M | Sell |
536,334
-40,500
| -7% | -$3.82M | 1.49% | 12 |
|
|
2017
Q3 | $51.3M | Sell |
576,834
-26,526
| -4% | -$2.02M | 1.75% | 10 |
|
|
2017
Q2 | $43.8M | Sell |
603,360
-3,833
| -0.6% | -$258K | 1.52% | 14 |
|
|
2017
Q1 | $39.6M | Sell |
607,193
-3,000
| -0.5% | -$189K | 1.45% | 12 |
|
|
2016
Q4 | $38.2M | Sell |
610,193
-27,351
| -4% | -$1.67M | 1.43% | 13 |
|
|
2016
Q3 | $40.2M | Sell |
637,544
-106,569
| -14% | -$6.9M | 1.52% | 10 |
|
|
2016
Q2 | $46.1M | Sell |
744,113
-51,342
| -6% | -$3.13M | 1.76% | 8 |
|
|
2016
Q1 | $45.4M | Buy |
795,455
+15,867
| +2% | +$884K | 1.73% | 9 |
|
|
2015
Q4 | $46.2M | Buy |
779,588
+70,351
| +10% | +$4.05M | 1.69% | 10 |
|
|
2015
Q3 | $38.6M | Buy |
709,237
+94,240
| +15% | +$6.13M | 1.51% | 12 |
|
|
2015
Q2 | $41.3M | Buy |
614,997
+62,053
| +11% | +$4.05M | 1.45% | 14 |
|
|
2015
Q1 | $32.4M | Buy |
552,944
+328,928
| +147% | +$19.9M | 1.13% | 20 |
|
|
2014
Q4 | $14.7M | Sell |
224,016
-2,700
| -1% | -$170K | 0.47% | 54 |
|
|
2014
Q3 | $13.1M | Sell |
226,716
-13,050
| -5% | -$725K | 0.44% | 58 |
|
|
2014
Q2 | $13.5M | Sell |
239,766
-1,200
| -0.5% | -$63K | 0.43% | 62 |
|
|
2014
Q1 | $12.4M | Sell |
240,966
-1,220
| -0.5% | -$61.7K | 0.4% | 82 |
|
|
2013
Q4 | $12.8M | Sell |
242,186
-15,382
| -6% | -$756K | 0.5% | 72 |
|
|
2013
Q3 | $11.5M | Buy |
257,568
+3,172
| +1% | +$141K | 0.51% | 70 |
|
|
2013
Q2 | $10.5M | Buy |
+254,396
| New | +$11.1M | 0.47% | 70 |
|
Other funds holding ABBV
VCM
VPM
Jupiter Asset Management's ABBV Position: Q1 2026 in Review
Jupiter Asset Management reduced its AbbVie (ABBV) stake by 1.2% in Q1 2026, selling an estimated $1.4M and leaving 529,252 shares worth $115M. The position accounts for 0.61% of the portfolio, ranked #40.
Jupiter Asset Management first reported a position in ABBV in Q2 2013 and has held it in 39 quarters since. The position peaked at $122M in Q4 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Jupiter Asset Management held 529,252 shares of AbbVie worth $115M as of Q1 2026.
- Jupiter Asset Management sold 6,324 AbbVie shares in Q1 2026, an estimated $1.4M.
- AbbVie made up 0.61% of Jupiter Asset Management's portfolio in Q1 2026, its #40 holding.
- Jupiter Asset Management first reported a position in AbbVie in Q2 2013 and has held it in 39 quarters since.
- Jupiter Asset Management's AbbVie position peaked at $122M in Q4 2025.
- 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Jupiter Asset Management's 13F filing for Q1 2026, filed 12 May 2026.